Compare TCMD & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | PACB |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.2M | 521.8M |
| IPO Year | 2016 | 2010 |
| Metric | TCMD | PACB |
|---|---|---|
| Price | $21.82 | $1.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $36.00 | $1.67 |
| AVG Volume (30 Days) | 366.6K | ★ 7.3M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $11.60 | $11.32 |
| Revenue Next Year | $9.14 | $12.14 |
| P/E Ratio | $85.71 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $13.14 | $1.07 |
| 52 Week High | $37.77 | $2.73 |
| Indicator | TCMD | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 47.26 |
| Support Level | $20.53 | $1.27 |
| Resistance Level | $26.49 | $1.47 |
| Average True Range (ATR) | 0.88 | 0.11 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 14.26 | 35.71 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.